Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.
|Articles|February 26, 2010
Genentech in drug discovery agreement
Author(s)Stephanie Sutton
The University of California, San Francisco (CA, USA; UCSF) has signed an agreement with Genentech with the aim of discovering and developing drug candidates for neurodegenerative diseases.
Advertisement
The University of California, San Francisco (CA, USA; UCSF) has signed an agreement with Genentech with the aim of discovering and developing drug candidates for neurodegenerative diseases.
Genentech will provide funding and its research acumen in neuroscience, and will collaborate with the university to identify small molecules. The drug discovery candidates will be based on prior academic research conducted at the university’s Small Molecule Discovery Center (SMDC) and discoveries at Genentech.
“What is transformative about this agreement from the university’s perspective is that it is a true collaboration between the UCSF and Genentech scientists, with the intent to generate drug candidates. This is different from a standard out-license or simple research collaboration,” Jim Wells, Chair of the Department of Pharmaceutical Chemistry in the UCSF School of Pharmacy, and a faculty affiliate of the California Institute for Quantitative Biosciences, explained in a
This is the first major collaboration the SMDC has formed with an industry partner. In addition to the financial support received from Genentech, there is also the potential for further funding in excess of $13 million if certain development and commercial milestones are met, plus royalties.
Advertisement
Related to this article
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Advertisement
Advertisement